[ET Net News Agency, 18 November 2024] Nomura lowered the target price for CSPC Pharma
(01093) to HKD7.02 from HKD8.46 and maintained the "buy" rating.
The research house said it lowers FY24F and FY25F revenue/earnings by 6.4%/8.9% and
11.4%/19.9%, given the weaker-than-expected results amid an unfavourable environment. (rc)